Which Risk Factors Causally Influence Dementia? A Systematic Review of Mendelian Randomization Studies by Kuzma E et al.
Journal of Alzheimer’s Disease 64 (2018) 181–193
DOI 10.3233/JAD-180013
IOS Press
181
Which Risk Factors Causally Influence
Dementia? A Systematic Review
of Mendelian Randomization Studies
Elz˙bieta Kuz´maa,1, Eilis Hannona,1, Ang Zhoub, Ilianna Louridaa, Alison Bethelc, Deborah A.
Levined, Katie Lunnona, Jo Thompson-Coonc, Elina Hyppo¨nenb and David J. Llewellyna,∗
aUniversity of Exeter Medical School, UK
bCentre for Population Health Research, University of South Australia, Adelaide, Australia
cNIHR CLAHRC South West Peninsula (PenCLAHRC), University of Exeter Medical School, Exeter, UK
dUniversity of Michigan and Veterans Affairs Center for Clinical Management Research, Ann Arbor, USA
Handling Associate Editor: Deborah Gustafson
Accepted 17 April 2018
Abstract.
Background: Numerous risk factors for dementia are well established, though the causal nature of these associations remains
unclear.
Objective: To systematically review Mendelian randomization (MR) studies investigating causal relationships between risk
factors and global cognitive function or dementia.
Methods: We searched five databases from inception to February 2017 and conducted citation searches including MR studies
investigating the association between any risk factor and global cognitive function, all-cause dementia or dementia subtypes.
Two reviewers independently assessed titles and abstracts, full-texts, and study quality.
Results: We included 18 MR studies investigating education, lifestyle factors, cardiovascular factors and related biomarkers,
diabetes related and other endocrine factors, and telomere length. Studies were of predominantly good quality, however eight
received low ratings for sample size and statistical power. The most convincing causal evidence was found for an association
of shorter telomeres with increased risk of Alzheimer’s disease (AD). Causal evidence was weaker for smoking quantity,
vitamin D, homocysteine, systolic blood pressure, fasting glucose, insulin sensitivity, and high-density lipoprotein cholesterol.
Well-replicated associations were not present for most exposures and we cannot fully discount survival and diagnostic bias,
or the potential for pleiotropic effects.
Conclusions: Genetic evidence supported a causal association between telomere length and AD, whereas limited evidence
for other risk factors was largely inconclusive with tentative evidence for smoking quantity, vitamin D, homocysteine, and
selected metabolic markers. The lack of stronger evidence for other risk factors may reflect insufficient statistical power.
Larger well-designed MR studies would therefore help establish the causal status of these dementia risk factors.
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INTRODUCTION
According to recent estimates and projections,
35.6 million older adults across the globe suffered
from dementia in 2010, and 115 million will have
dementia in 2050 [1]. Currently there are no disease
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modifying treatments, but if we reduced the preva-
lence of seven modifiable risk factors (diabetes,
midlife hypertension, midlife obesity, depression,
physical inactivity, smoking, low education) by 10%
per decade, 8.8 million cases of Alzheimer’s dis-
ease (AD) may potentially be prevented worldwide
in 2050 [2]. This illustrates the potential of demen-
tia prevention but relies on the assumption that these
risk factors are causally associated. A number of
dementia risk factors have been identified in epi-
demiological research. However, these observational
findings are challenged by the inability to distin-
guish cause from effect and confounders inducing
(or masking) an association. Randomized controlled
trials (RCTs) are not a viable option for establishing
causal effects where there is a long latency from expo-
sure to disease onset, or it is unethical to administer
(or withdraw) an exposure. Mendelian randomization
(MR) is an alternative approach which uses genetic
variation as an instrument to assign participants to
exposure groups, akin to arms of a naturally occurring
randomized controlled trial [3, 4]. As an individ-
ual’s genotype is randomly assigned at conception,
it cannot be altered by either the outcome of interest
(reverse causation) or confounders, resolving the two
main issues in observational studies. Genetic vari-
ants are selected as instrumental variables (IVs) when
they are robustly associated with the exposure, with
the fundamental assumption that they are associated
with the outcome through the exposure (Fig. 1). It
is assumed that there is no direct path between the
genetic instrument and the outcome. As MR can be
a powerful tool to examine causality, we conducted a
systematic review of MR studies investigating causal
relationships between risk factors and global cogni-
tive function or dementia.
METHODS
We conducted this systematic review following
general principles outlined by the Centre for Reviews
and Dissemination [5].
Search strategy
Following a pre-defined protocol (Supplementary
Methods), an information specialist (AB) developed
a search strategy in collaboration with dementia
and methods experts (EK, IL, DJL, JTC, KL, EHy)
including subject headings and free text terms rel-
evant to dementia, cognition and MR. The search
strategy developed for Medline is provided in
Risk factor 
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Genetic 
instrument
Confounders
Fig. 1. Schematic of the principles of Mendelian randomization.
Mendelian randomization can be used to test for a causal relation-
ship between a risk factor and outcome, indicated here with the
red arrow. A genetic instrument (e.g., a single nucleotide polymor-
phism) associated with the risk factor (blue arrow) can be used as
an instrumental variable to effectively randomly assign individu-
als to exposure groups. Reverse causation can be excluded as it
is not possible for the outcome to influence a genotype which is
established at conception. One important assumption is that there
is no association between the genetic instrument and the outcome
except via the risk factor (i.e., the dashed arrow does not exist).
Supplementary Figure 1. We searched five databases
from inception to 16 February 2017 with no lan-
guage restrictions: Medline, Embase, PsycINFO
(via OvidSP), BIOSIS Citation Index (via Web of
Science) and the Cochrane Central Register of Con-
trolled Trials (Central). We also conducted forward
and backward citation searches of included publica-
tions via Web of Science and Scopus.
Study selection and data extraction
We included studies using MR to investigate the
association between any risk factor and all-cause
dementia, dementia subtypes, global cognitive func-
tion, or cognitive impairment. When selecting studies
for inclusion we broadened the definition of MR by
Lawlor and colleagues [6] to include any study that
uses genetic variation as a proxy for an exposure
to make causal inferences. Therefore, we retained
studies that did not quantify the causal relation-
ship but investigated the effect of a genetic IV on
the outcome. Non-genetic studies, genetic studies
other than MR, studies with outcomes not directly
related to the clinical syndrome of dementia (e.g.,
neuroimaging, domain specific cognitive tests) and
animal studies were excluded. We also excluded case
reports, narrative reviews, letters, editorials, opinions
and conference abstracts. Two reviewers (EK, IL)
independently screened titles and abstracts using pre-
defined inclusion and exclusion criteria. Full-texts
were also screened independently by the same two
reviewers and discussed with a third reviewer with
particular expertise in MR (EHa). Key data were
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extracted by one reviewer (EK) and checked by two
reviewers (EHa, IL). Where exposures were tested
with multiple IVs, results based on the strongest IV
(ranked by F statistics) were considered as primary
analyses and results using alternative IVs are included
in Additional files. If results from multiple cohorts
were combined, we extracted only pooled findings.
We also tried to contact corresponding authors of
studies where relevant data was not fully reported
[7–9] and received additional data for one study [9].
Risk of bias
The risk of bias of included studies was assessed
independently by two reviewers (EK, EHa) with
discrepancies resolved by discussion using the Q-
Genie tool [10], developed and validated specifically
to measure the quality of genetic studies with 11
items assessing study rationale, risk of bias, statis-
tical power and appropriateness of conclusions on a
seven-point Likert scale [10].
Data synthesis
Extracted data were synthesized narratively
because meta-analyses could not be conducted due
to a wide range of exposures, IVs, outcomes, and
statistical methods used in included studies. Main
findings were categorized by exposure. Studies varied
in their approaches to multiple testing, in part due to
differing numbers of exposures and outcomes tested.
For consistency we presented uncorrected results and
considered p values < 0.05 statistically significant.
Where applicable, we indicated which results were
adjusted for multiple testing in the original publica-
tion.
RESULTS
We identified 315 records from electronic database
searches. After removing duplicates (114 records),
we excluded 152 records based on the title and
abstract screening. We reviewed full-texts of 22 arti-
cles, 17 of which met our inclusion criteria. We
identified one additional study [8] via backward cita-
tion searches of the 17 included studies, so in total 18
studies were eligible for inclusion in our systematic
review (Supplementary Figure 2). Key characteris-
tics of included studies are shown in Supplementary
Table 1. These focused on a wide range of exposures:
education [11, 12], lifestyle factors [12–16], cardio-
vascular factors and related biomarkers [7–9, 12,
17–19], diabetes related and other endocrine factors
[12, 20–24], and telomere length [25], and dementia-
related outcomes: global cognitive function [8, 9, 14,
15, 20, 22, 24], cognitive impairment [13], demen-
tia probability [11, 17, 21], all-cause dementia [7]
and AD [12, 16–19, 21, 23, 25]. While the major-
ity of studies were based on populations of European
ancestry, three were Asian [14, 22, 24] and one was
mixed [19]. Three studies [13, 14, 22] included only
men, one only women [24]. Analytic sample sizes
ranged from 570 [7] to 54,162 [12, 16, 21, 23, 25], and
all studies involved middle-aged and/or older partici-
pants. There was variety in the statistical approaches
employed for MR: 15 studies derived causal estimates
by either two-stage least squares regression [7, 14, 15,
20–22], ratio of coefficients [11, 18, 19, 24], inverse-
variance weighted combination of summary statistics
from a genome-wide association study (GWAS) [12,
17, 21, 23, 25] or weighted generalized linear regres-
sion for correlated single nucleotide polymorphisms
(SNPs) [16]. Three studies only performed an asso-
ciation analysis of the genetic instrument on the
outcome [8, 9, 13]. The studies used either a sin-
gle genetic variant [8, 9, 13–15], a combination of
genetic variants, sometimes combined into a genetic
risk score (GRS) [11, 12, 16–24], or both [7, 25] as
IVs. The majority of included studies were of good
overall quality, with three studies [7, 8, 13] rated as
moderate (Supplementary Table 2). However, eight
studies [7, 8, 11, 13, 14, 20, 22, 24] had low ratings
(<4/7) regarding the sample size and statistical power.
Nine studies performed multiple tests, either consid-
ering multiple risk factors, IVs or outcomes [7, 9,
12, 16–18, 21, 23, 24] however adjustment for mul-
tiple comparisons was rare and handling of missing
phenotypic data often not addressed.
Education
Two studies examined genetic evidence for the
causal association between education and dementia
probability [11] or AD [12]. The causal estimates
were in the expected direction with lower demen-
tia probability [11] or odds of AD [12] for each
year of education or completion of university, though
these associations were not statistically significant
(p > 0.10 for all comparisons; Table 1).
Lifestyle factors
Two studies [12, 15] investigated causal effects
of smoking in participants of European ancestry.
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Table 1
Results of included studies investigating education and lifestyle factors
Study Methods Results
Exposure
(analytic n/casesa)
MR estimate (95% CI)
Nguyen et al., 2016 [11] GRS is weighted sum of risk
alleles (R2 = 0.11%);
separate-sample 2SLSb
Dementia probability
Education (7,981) IV estimated change in dementia probability per education
year = –0.011 (–0.024, 0.002), p = 0.11
Østergaard et al., 2015
[12]
Inverse-variance weighted
combination of summary
statisticsc
AD
Education, smoking
(54,162 / 17,008)
IV estimated OR per unit in log odds of university completion = 0.95
(0.67, 1.34), p = 0.752
IV estimated OR per education year = 0.71 (0.48, 1.06), p = 0.097
IV estimated OR per unit in log odds of smoking initiation = 0.70 (0.37,
1.33), p = 0.278
IV estimated OR per 10 cigarettes/day = 0.67 (0.51, 0.89),
p = 6.5 × 10−3
North et al., 2015 [15] 2SLS regression within each
cohort and combined with a
random effects
meta-analysis
General fluid cognition
Smoking (13,004d) IV estimated difference between current and ex-smoker = 0.029
(–1.394, 1.453)
Almeida et al., 2014 [13] Association test of IV on
outcome
Cognitive impairment
Alcohol (3,542 / 502) OR for AA versus GG in rs1229984 = 1.35 (0.29, 6.27)
OR for GA versus GG in rs1229984 = 1.05 (0.71, 1.55)
Au Yeung et al., 2012 [14] 2SLS regression; R2 = 3% Global cognition
Alcohol (2,284) IV estimated change per 10g ethanol/day = 0.06 (–0.22, 0.34)
Kwok et al., 2016 [16] Weighted generalized linear
regression for correlated
SNPse
AD
Coffee (54,162 / 17,008) IV estimated OR per cup per day = 1.17 (0.96, 1.43)f
AD, Alzheimer’s disease; CI, Confidence Interval; GRS, genetic risk score; IV, instrumental variable; MR, Mendelian randomization; OR,
odds ratio; R2, percentage of variance explained; 2SLS, two-stage least squares. aReported for binary outcomes only. bAdjusted for sex,
age at first outcome assessment, age2, early life socioeconomic status, population eigenvectors. cStudy applied a Bonferroni corrected
significance threshold of p < 3.8 × 10−3. dTotal number of participants with age, sex, genotype, smoking status and general fluid intelligence
factor, and restricted to those included also in the observational analysis. eBonferroni corrected significance level of 0.002. f IV estimated
OR per cup per day = 1.29 (0.82, 2.03) after exclusion of 4 SNPs associated with body weight or lipids and 2 SNPs previously not associated
with coffee.
North and colleagues [15] used IVs from CHRNA5
or CHRNA3 and reported no evidence for a causal
association between current smokers and global fluid
cognition compared to former smokers. Østergaard
and colleagues [12] found no evidence for a causal
association between smoking initiation (BDNF) and
odds of AD. However, elevated smoking quantity
(CHRNA3, LOC100188947 and CYP2A6) was sig-
nificantly associated with lower odds of AD [12]
(Table 1).
Two studies conducted in men only evaluated the
association between alcohol consumption and cogni-
tive impairment [13] or global cognition [14]. One
study [13] based on participants of European ances-
try found no association with cognitive impairment
for rs1229984 in ADH1B where the minor allele
(A) has previously been associated with lower alco-
hol consumption [26]. There was also no evidence
for a causal association in the other study of global
cognition conducted in Chinese men using rs671 in
ALDH2 as the IV [14] (Table 1).
One study [16] investigating coffee consumption
found no genetic evidence supporting a causal asso-
ciation with odds of AD (Table 1).
Cardiovascular factors and related biomarkers
Three studies [12, 17, 18] investigated cardiovas-
cular factors and their association with dementia risk.
Mukherjee and colleagues [17] examined whether
there is a causal link between body mass index
(BMI) and either dementia probability or AD. Nei-
ther BMI nor any of the mechanism-specific aspects
of obesity (e.g., adipogenesis, appetite or cardiopul-
monary processes) were significantly associated with
dementia probability [17] (Table 2). While there was
also no significant association with BMI, the group
of “unspecific cellular processes” was statistically
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Table 2
Results of included studies investigating cardiovascular factors and related biomarkers
Study Methods Results
Exposure
(analytic n/casesa)
MR estimate (95% CI)
Mukherjee et al., 2015
[17]
GRS is weighted sum of
alleles (R2 ∼1%);
association test of GRS on
outcome for ADGC and
HRS; inverse variance
weighted summary statistic
for GERAD; ADGC and
GERAD results combined
with fixed effects
meta-analysisb
Dementia probability
BMI (dementia
probability: 8,403;
AD: 30,146 / 13,256)
IV estimated OR per BMI GRS unit = 1.00 (0.75, 1.32), p = 0.98
IV estimated OR per BMI adipogenesis GRS unit = 1.05 (0.42, 2.62), p = 0.92
IV estimated OR per BMI appetite GRS unit = 1.02 (0.72, 1.44), p = 0.92
IV estimated OR per BMI cardiopulmonary processes GRS unit = 1.09 (0.42,
2.83), p = 0.86
IV estimated OR per BMI unspecified cellular processes GRS unit = 0.87
(0.46, 1.66), p = 0.68
AD
IV estimated OR per BMI GRS unit = 0.95 (0.91, 1.00), p = 0.058
IV estimated OR per BMI adipogenesis GRS unit = 1.07 (0.90, 1.27), p = 0.450
IV estimated OR per BMI appetite GRS unit = 0.96 (0.90, 1.02), p = 0.160
IV estimated OR per BMI cardiopulmonary processes GRS unit = 1.21 (1.00,
1.47), p = 0.055
IV estimated OR per BMI unspecified cellular processes GRS unit = 0.81
(0.74, 0.90), p = <0.001
Østergaard et al., 2015
[12]
Inverse-variance weighted
combination of summary
statisticsc
AD
BMI, SBP, total
cholesterol, HDL,
LDL, triglycerides
(54,162 / 17,008)
IV estimated OR per BMI SD = 0.99 (0.80, 1.19), p = 0.779
IV estimated OR per SBP SD = 0.75 (0.62, 0.91), p = 3.4 × 10−3
IV estimated OR per total cholesterol SDd = 1.94 (1.79, 2.10), p = 3.1 × 10−56
IV estimated OR per HDL SDe = 0.75 (0.69, 0.82), p = 1.0 × 10−11
IV estimated OR per LDL SDf = 2.31 (2.12, 2.50), p = 3.0 × 10−87
IV estimated OR per triglycerides SD = 0.96 (0.87, 1.07), p = 0.482
Proitsi et al., 2014 [18] GRS is standardized
weighted sum of risk
alleles (total cholesterol
full GRS R2 = 3.59%,
specific GRS R2 = 0.31%;
HDL full GRS R2 = 4.19%,
specific GRS R2 = 0.02%;
LDL full GRS R2 = 1.83%,
specific GRS R2 = 0.28%;
triglycerides full GRS
R2 = 4.34%, specific GRS
R2 = 0.50%); where GRS
risk prediction R2 ≥ 1.5%
ratio of coefficients
methodg; where GRS risk
prediction R2 < 1.5%
inverse-variance weighted
combination of summary
statistics. Results from each
cohort were combined with
inverse-variance fixed
effects meta-analysis
AD
Total cholesterol, HDL,
LDL, triglycerides
IV estimated OR per total cholesterol GRS unit (full GRS) = 0.954 (0.76,
1.21), p = 0.688
IV estimated OR per total cholesterol GRS unit (trait specific GRS) = 1.036
(0.99, 1.09), p = 0.144
IV estimated OR per HDL GRS unit (full GRS) = 1.005 (0.82, 1.24), p = 0.962
IV estimated OR per HDL GRS unit (trait specific GRS) = 1.463 (1.05, 2.04),
p = 0.023
IV estimated OR per LDL GRS unit (full GRS) = 0.901 (0.65, 1.25), p = 0.530
IV estimated OR per LDL GRS unit (trait specific GRS) = 0.572 (0.24, 1.34),
p = 0.199
IV estimated OR per triglycerides GRS unit (full GRS) = 1.104 (0.89, 1.37),
p = 0.362
IV estimated OR per triglycerides GRS unit (trait specific GRS) = 0.872 (0.46,
1.65), p = 0.676
Cruchaga et al., 2012
[7]
2SLS regressionh; R2 = 8.2% Dementia severity at baseline
CSF APOE levels
(570 / 146)
APOE p = 3.06 × 10−5
Dementia severity at 36 months
APOE p = 2.06 × 10−6
Case-control status for AD at baseline
significant associations per CSF APOE levels
(continued)
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Table 2
(continued)
Study Methods Results
Exposure
(analytic n/casesa)
MR estimate (95% CI)
Marioni et al., 2011 [8] Association of IV on outcome
in each cohort were
combined with inverse
variance meta-analysisi
General cognitive factor
Fibrinogen (4,248) rs2227412 (GA versus GG and AA) p = 0.14
Quinn et al., 2015 [9] Association test of IV on
outcomej; (D-dimer
R2 = 1.8%; fibrinogen
R2 = 2%; plasminogen
activator inhibitor
R2 = 3.7%; von Willebrand
factor; R2 = 13%)
General cognitive factork
D-dimer, fibrinogen,
plasminogen activator
inhibitor, von
Willebrand factor
(12,757–13,142)
Difference between GT and GG at rs12029080 (D-dimer) = –0.010 (–0.073;
0.054), p = 0.765
Difference between TT and GG at rs12029080 (D-dimer) = 0.002 (–0.061;
0.065), p = 0.951
Difference between AG and AA at rs1800789 (fibrinogen) = –0.022 (–0.115;
0.071), p = 0.646
Difference between GG and AA at rs1800789 (fibrinogen) = –0.040 (–0.132;
0.052), p = 0.394
Difference between AG and AA at rs2227631 (plasminogen activator
inhibitor) = 0.029 (–0.008; 0.065), p = 0.121
Difference between GG and AA at rs2227631 (plasminogen activator
inhibitor) = 0.036 (–0.016; 0.087), p = 0.172
Difference between GA and GG at rs1063857 (von Willebrand factor) = –0.05
(–0.055; 0.045), p = 0.832
Difference between AA and GG at rs1063857 (von Willebrand factor) = 0.006
(–0.047; 0.058), p = 0.824
Hu et al., 2016 [19] Ratio of coefficients method AD
Homocysteine
(9,397 / 4,120)
IV estimated OR per SD unit of homocysteine (overall) = 3.37 (1.90, 5.95),
p = 2.9 × 10−5
IV estimated OR per SD unit of homocysteine (Caucasian) = 1.67 (0.95, 2.95),
p = 0.75
IV estimated OR per SD unit of homocysteine (Asian) = 6.69 (2.13, 20.99),
p = 0.0011
IV estimated OR per SD unit of homocysteine (other) = 12.6 (3.15, 50.61),
p = 3.4 × 10−3
AD, Alzheimer’s disease; ADGC, Alzheimer’s Disease Genetics Consortium; APOE, apolipoprotein E; BMI, body mass index; CI, con-
fidence interval; CSF, cerebrospinal fluid; GERAD, Genetic and Environmental Risk for Alzheimer’s Disease consortium; GRS, genetic
risk score; HDL, high-density lipoprotein cholesterol; IV, instrumental variable; LDL, low-density lipoprotein cholesterol; MR, Mendelian
randomization; OR, odds ratio; SBP, systolic blood pressure; SD, standard deviation; 2SLS, two-stage least squares. aReported for binary
outcomes only. bADGC models adjusted for study, 3 genetic principal components; HRS models adjusted for 6 genetic principal components,
age and sex. cStudy applied a Bonferroni corrected significance threshold of p < 3.8 × 10−3. dIV estimated OR per total cholesterol SD = 1.04;
95% CI: 0.95–1.13, p = 0.84 after exclusion of SNPs associated with AD. eIV estimated OR per HDL SD = 1.01, 95% CI: 0.93–1.09, p = 0.87
after exclusion of SNPs associated with AD. f IV estimated OR per LDL SD = 1.07, 95% CI: 0.98–1.17, p = 0.14 after exclusion of SNPs
associated with AD. gAll analyses of GRS on AD adjusted for the first 4 genetic principal components, additional adjustment for genotyping
batch in Institute of Psychiatry Plus data only. hAdjustment strategy unclear. iAdjusted for age and sex. jAdjusted for age, sex, Mill Hill
test, household income, education, blood pressure, heart rate, body mass index, waist-hip ratio, alcohol consumption, smoking, vascular and
cognitive comorbidity history. kEstimates (except for fibrinogen) provided from the authors at request.
significantly associated with odds of AD [17]. Sim-
ilarly, Østergaard and colleagues [12], using an IV
derived from a largely overlapping set of SNPs, did
not find evidence to support a causal association
between BMI and AD (Table 2).
Østergaard and colleagues [12] also investigated
systolic blood pressure (SBP) reporting that higher
SBP significantly lowered the odds of AD (Table 2),
a finding that survived Bonferroni correction for the
multiple exposures they considered.
Two studies [12, 18] examined the link between
total cholesterol, high-density lipoprotein cholesterol
(HDL), low-density lipoprotein cholesterol (LDL),
triglycerides and AD. Primary analyses conducted
by Østergaard and colleagues [12] found statisti-
cally significant associations between both higher
total cholesterol and LDL and higher odds of AD
whereas higher HDL was linked with lower odds
of AD. However, these associations were no longer
significant after excluding rs6857 near APOE and
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rs1883025 from ABCA1 (both associated with AD)
from the GRS IV, suggesting the initial results may
be driven by pleiotropic effects of these excluded
SNPs [12]. The study by Proitsi and colleagues
[18] found no significant associations between total
cholesterol, HDL, or LDL and odds of AD based
on either individual level data (Table 2) or summary
data (Supplementary Table 3). When instrumented
by phenotype specific GRSs (limited to SNPs only
associated with one exposure) calculated with sum-
marized GWAS results, higher HDL was significantly
associated with higher odds of AD but there was
no link with either total cholesterol or LDL [18]
(Table 2). This significant relationship may also be
explained by pleiotropic effects of rs1883025, which
was excluded in sensitivity analyses by Østergaard
and colleagues due to its association with AD [12].
Taken together, there was no consistent evidence for
a causal association between cholesterol levels and
AD. Further, there was also no evidence of a causal
association between triglycerides and odds of AD
in either study [12, 18] (Table 2 and Supplementary
Table 3).
APOE genotype is a well-known genetic risk
factor for AD [27, 28]. Cruchaga and colleagues
[7] investigated the causal effects of cerebrospinal
APOE protein levels using MR and reported signif-
icant associations [7] with three related outcomes
(dementia severity at baseline and 3-year follow-
up, and baseline AD status). However, they did not
provide estimates of the effect size or confidence
intervals to allow for a more detailed evalua-
tion of their findings (Table 2 and Supplementary
Table 3).
Two studies [8, 9] examined fibrinogen in relation-
ship to global cognition with neither study finding
genetic evidence for a causal relationship. In addition
to fibrinogen, Quinn and colleagues [9] also investi-
gated D-dimer, plasminogen activator inhibitor and
von Willebrand factor but found no evidence for an
association between any of the IVs for these measures
and global cognition (Table 2).
One study [19] investigating causal effects of
homocysteine in a heterogeneous population of
mixed ancestry found that increased homocysteine
levels were associated with increased odds of AD.
However, the association was no longer statistically
significant when the sample was restricted to Cau-
casians (Table 2), which is likely important as the
effects of the IV on AD were estimated in a European
population.
Diabetes related and other endocrine factors
Two studies [12, 21] examined the causal rela-
tionship between type 2 diabetes (T2D) or related
phenotypes and odds of AD using the International
Genomics of Alzheimer’s Project (IGAP) GWAS
results. One of these studies [21] also investigated
the link with dementia probability in the Health and
Retirement Study (HRS). Although they selected dif-
ferent sets of SNPs for the T2D GRS (49 [12] versus
39 [21] SNPs), neither study [12, 21] found a sig-
nificant association with T2D. There was also little
evidence to support the relationship with T2D related
phenotypes, as the nominally significant finding by
Walter and colleagues [21] for insulin sensitivity did
not survive Bonferroni multiple testing correction
(p = 0.08). However, higher fasting glucose was sig-
nificantly associated with increased odds of AD after
excluding one SNP (rs11039149) which is possibly
pleiotropically associated with AD [12] (Table 3).
One study used a combination of genetic variants
(rs2282679 in GC, rs12785878 near DHCR7,
rs10741657 near CYP2R1 and rs6013897 in
CYP24A1), to examine the association between
genetically instrumented 25-hydroxyvitamin D
[25(OH)D] and AD risk, reporting some evidence
for an inverse association (odds ratio [OR] = 1.25,
95% confidence interval [CI] = 1.03–1.51, p = 0.02)
[23]. However, when rs2282679 in GC was excluded
due to potential pleiotropic effects [29, 30], there
was no evidence for the association with AD
(OR = 1.19, 95% CI = 0.96, 1.45, p = 0.11). Further
analyses separating the genetic instrument into
SNPs involved in vitamin D metabolism (rs2282679
and rs10741657) and synthesis (rs12785878 and
rs6013897), again suggested the association may be
driven by rs2282679 in GC [23] (Table 3). Another
study used two SNPs in the GC as a GRS, and
found no support for a causal association with global
cognition [20]. Two studies in Chinese men and
women, respectively reported no significant associa-
tion between testosterone [22] or 17-estradiol [24]
and global cognition (Table 3).
Telomere length
Shorter telomeres were statistically significantly
associated with increased odds of AD in a study
using the IGAP data [25] (Table 3). Additional results
for individual SNPs are provided in Supplementary
Table 4 with two out of seven SNPs (rs2736100 and
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Table 3
Results of included studies investigating diabetes related and other endocrine factors, and telomere length
Study Exposure
(analytic n/casesa)
Methods Results
MR estimate (95% CI)
Østergaard et al., 2015
[12]
Inverse-variance weighted
combination of summary
statisticsb
AD
T2D, fasting glucose,
insulin resistance
(54,162 / 17,008)
IV estimated OR per unit in log odds of T2D = 1.02 (0.97, 1.07), p = 0.535
IV estimated OR per fasting glucose SD = 1.12 (0.97, 1.30), p = 0.112c
IV estimated OR per log-fasting insulin SD = 1.32 (0.88, 1.98), p = 0.177
Walter et al., 2016 [21] GRS is weighted sum of risk
alleles converted to a
probability predicting
dementia probability (logit)
T2D GRS R2 = 1.98%
adiposity GRS R2 = 0.09%
-cell function GRS
R2 = 1.28% insulin
sensitivity GRS R2 = 0.29%
other GRS R2 = 0.30%;
2SLS regression for
dementia probabilityd;
inverse-variance weighted
combination of summary
statistics for AD
Dementia probability (logit)
T2D (dementia
probability: 8,501;
AD: 54,162 / 17,008)
IV estimated change per predicted risk of T2D = 0.04 (–0.92, 1.01)
IV estimated change per predicted risk of T2D (adiposity SNPs) = 2.23 (–2.12,
6.59)
IV estimated change per predicted risk of T2D (-cell function SNPs) = –0.49
(–1.70, 0.73)
IV estimated change per predicted risk of T2D (insulin sensitivity
SNPs) = 1.59 (–0.99, 4.18)
IV estimated change per predicted risk of T2D (other SNPs) = 0.21 (–2.28,
2.71)
AD
IV estimated OR per unit in log odds of T2D = 1.01 (0.96, 1.06), p = 0.79
IV estimated OR per unit in log odds of T2D (adiposity SNPs) = 0.93 (0.74,
1.15), p = 0.49
IV estimated OR per unit in log odds of T2D (-cell function SNPs) = 1.00
(0.94, 1.07), p = 0.89
IV estimated OR per unit in log odds of T2D (insulin sensitivity SNPs) = 1.17
(1.02, 1.34), p = 0.02e
IV estimated OR per unit in log odds of T2D (other SNPs) = 0.90 (0.79, 1.04),
p = 0.14
Kueider et al., 2016 [20] GRS is sum of minor alleles;
2SLS regressionf
Global cognition
Vitamin D (848) IV estimated change per ng/mL of 25(OH)D = 0.01 (–0.01, 0.06), p = 0.41
Mokry et al., 2016 [23] Inverse-variance weighted
combination of summary
statistics; R2 = 2.44%
AD
Vitamin D
(54,162 / 17,008)
IV estimated OR per SD decrease in natural log 25(OH)D = 1.25 (1.03, 1.51),
p = 0.02g
IV estimated OR per SD decrease in natural log 25(OH)D (metabolism
SNPs) = 1.46 (1.03, 2.07), p = 0.03
IV estimated OR per SD decrease in natural log 25(OH)D (synthesis
SNPs) = 1.17 (0.93, 1.46), p = 0.17
Zhao et al., 2016 [22] 2SLS regression; R2 = 4.1% Global cognition
Testosterone (4,122) IV estimated change per testosterone nmol/L = 0.06 (–0.002, 0.12), p = 0.06
Au Yeung et al., 2016
[24]
Ratio of coefficients;
R2 = 4.9%;
Global cognition
17-estradiol (3,066)
IV estimated change per log 17-estradiol pmol/L = 0.39 (–0.87, 1.65)
Zhan et al., 2016 [25]
Telomere length
(54,162 / 17,008)
Inverse-variance weighted
combined summary
statistics
AD
IV estimated OR per SD decrease of telomere length = 1.36 (1.12, 1.67),
p = 0.002
AD, Alzheimer’s disease; CI, confidence interval; GRS, genetic risk score; MR, Mendelian randomization; OR, odds ratio; SD, standard
deviation; SNP, single nucleotide polymorphism; T2D, type 2 diabetes; 2SLS, two-stage least squares; 25(OH)D, 25-hydroxyvitamin D.
aReported for binary outcomes only. bStudy applied a Bonferroni corrected significance threshold of p < 3.8 × 10−3. cIV estimated OR per
fasting glucose SD = 1.19; 95% CI: 1.03–1.37, p = 0.02 after exclusion of 1 SNP associated with AD. dAdjusted for age, sex and 6 population
eigenvectors in analyses of dementia probability. eBonferroni corrected p = 0.08. f Adjusted for age, sex, education, apolipoprotein E 4 status,
depressive symptoms, body mass index, and season of 25(OH)D collection. gIV estimated OR per SD decrease in natural log 25(OH)D = 1.19
(0.96, 1.45), p = 0.11 and 1.26 (1.00, 1.60), p = 0.05 after exclusion of rs2282679 due to potential pleiotropic effects and rs12785878 as an
ancestry marker, respectively.
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rs9420907) providing evidence for a causal associa-
tion with AD when used as single SNP IVs [25].
DISCUSSION
MR is increasingly used to provide support for
causal effects where RCTs are impractical or unethi-
cal. In this systematic review, we included 18 studies
using this methodology to examine causal rela-
tionships between risk factors and global cognitive
function or dementia. Evidence for a causal associa-
tion was seen for shorter telomeres and higher odds of
AD demonstrating that MR can provide novel causal
insight for exposures that an RCT cannot be designed
for. There was also some suggestion of a causal rela-
tionship between higher SBP and higher smoking
quantity with lower odds of AD, and higher fasting
glucose, HDL, insulin sensitivity and homocysteine
with higher odds of AD. Evidence for the role of
vitamin D in AD was inconclusive, with some evi-
dence for a causal association obtained from a study
using a variant coding the vitamin D binding protein.
While there was no evidence to support causal rela-
tionships with other risk factors, we cannot rule them
out because for most exposures, data was only avail-
able from one study, with relatively modest sample
sizes (n < 10,000) in half of the studies.
Power in MR studies is determined largely by the
strength of the instrument, typically evaluated as the
proportion of variation in the exposure explained
by the IV; the weaker the instrument (indicated by
smaller R2), the larger the sample size required to
achieve the same power. In Fig. 2, we present power
calculations for diverse but realistic scenarios for
instruments with R2 ranging from 0.1% to 5.0%,
with an odds ratio (OR) of 1.5 (binary outcome)
or 0.15 standard deviations (standardized continuous
outcome). For example, for a binary outcome with a
weak IV predicting only 0.1% of the variance in the
exposure, a sample size of over 200,000 is required
to achieve 80% power. Even studies using the IGAP
data (n = 54,162) are likely to be underpowered
to detect small effects if they use weak instru-
ments. When using a weak genetic IV for education
(R2 = 0.11%) Nguyen and colleagues [11] did not
find a significant causal relationship with dementia
probability. However, when they used a stronger non-
genetic IV (compulsory schooling laws, R2 = 0.29%)
with a larger sample size, each year of education
reduced the dementia probability by 0.095 (95%
confidence interval (CI): –0.148, –0.042; p < 0.001),
demonstrating their MR analysis was possibly
underpowered.
One study using summary statistics from genome-
wide association studies to maximize power, found
a significant causal effect for shorter telomeres and
higher odds of AD in line with previous non-genetic
studies [31]. The causal nature of the association is
an important finding given that telomere length has
been implicated in AD pathology (tau hyperphos-
phorylation and A accumulation) and pathogenesis
(oxidative stress and inflammation) [32].
One [12] of the two MR studies [12, 15] sug-
gested that the association between higher smoking
quantity and lower AD risk may be due to altered
nicotinic receptor function. However, there is insuffi-
cient evidence for neuroprotective effects of nicotine
in humans and findings indicating smoking might
decrease AD risk are likely an artefact of survival
bias [33] present also in MR studies. This signif-
icant finding may also reflect a diagnostic bias as
smokers are more likely to suffer a stroke [34] and
therefore to be diagnosed with vascular or mixed
dementia. Non-genetic observational studies sug-
gested light to moderate alcohol consumption may
decrease dementia risk [35] but MR studies included
in our systematic review did not support a causal
association with dementia-related outcomes [13, 14].
Another MR study investigating the link between
alcohol consumption and specific cognitive domains
in participants of European ancestry (n = 34,452) also
did not provide evidence for causal associations with
immediate and delayed word recall, verbal fluency
and processing speed [36].
While higher genetically determined SBP was sta-
tistically significantly associated with lower AD risk,
it was also related to higher probability of taking
antihypertensive medication which may influence
this relationship [12]. A recent systematic review
of non-genetic observational studies suggested anti-
hypertensive medication might be protective against
AD [37]. However, another systematic review and
meta-analysis did not find a significant association
of antihypertensive medication with incident all-
cause dementia when restricted to RCTs (OR = 0.89,
95% CI = 0.74, 1.07) [38]. As the link between SBP
and all-cause dementia or vascular dementia was
not investigated by our included studies, we cannot
exclude a potential diagnostic bias as those with vas-
cular risk factors may be more likely to receive a diag-
nosis of vascular or mixed dementia rather than AD.
One study [19] suggested a causal association
between increased homocysteine levels and increased
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Fig. 2. Power curves for genetic instruments with R2 of 0.1%, 0.2%, 0.4%, 0.8%, 1.6%, and 5.0% when outcomes are binary (A) and
continuous (B). The power functions were taken from Burgess [46]. For binary outcomes, two-sided type 1 error, effect size (in odds ratio for
1 standard deviation (SD) increase in the exposure), and case to control ratio were set to be 0.05, 1.5, and 1 : 3, respectively. For continuous
outcomes, two-sided type 1 error and effect size (in SD for 1 SD increase in the exposure) were set to be 0.05 and 0.15, respectively.
odds of AD. However, the study population was of
mixed ancestry and stratified analyses revealed sta-
tistically significant associations in a population of
Asian and other ancestry but not in Caucasians [19].
Two sample MR used in this study assumes that the
genetic effects that are being compared are derived
from the same population [39], questioning the appro-
priateness of basing the primary result on a mixed
population when the IGAP data used was limited to
European ancestry.
For vitamin D, in line with previous non-genetic
observational findings [40], there was some evidence
for a causal link with AD [23]. However, this associa-
tion appeared to be driven by a SNP in the GC, coding
the vitamin D binding protein. As GC polymorphisms
are the primary determinants of circulating concen-
trations of vitamin D binding protein rather than
25(OH)D [41], and as they have been shown to affect
25(OH)D bioavailability to the target cells [29], it is
difficult to directly translate related findings to reflect
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possible causal associations with 25(OH)D concen-
trations [42]. Interestingly, while another study which
used two SNPs in GC as IV [20] did not find any asso-
ciation with global cognition, there was evidence for
a causal association with specific cognitive domains
such as executive function, psychomotor speed and
confrontational naming. Other studies have suggested
significant links with word recall for SNPs in GC [43]
and VDR [44] genes, and with psychomotor speed for
a SNP in the VDR gene [44], highlighting the interest
in further studies using variants involved in vitamin
D metabolism.
We have conducted the first systematic review of
studies that applied an MR framework to test for
causal associations between risk factors and global
cognitive function or dementia. Our review consid-
ered a broad range of exposures due to a comprehen-
sive search strategy including forward and backward
citation searches and no restrictions regarding pub-
lication date or language. As most of the included
studies did not perform power calculations, it is
unclear whether there are few causal relationships,
or the data are insufficient to detect the magnitude of
the effect. Moreover, results of MR and observational
studies may represent different underlying processes
as exposures in MR studies reflect lifelong differ-
ences determined by differences in genetic variants
[45] whereas exposures in observational studies are
determined by genetic and non-genetic influences at
a given point in time. A number of studies used a two
sample approach, taking advantage of GWAS with
the largest sample sizes to date for each risk factor and
the summary statistics for AD published by the IGAP
consortium. Many of the included risk factors have
a polygenic architecture where each associated SNP
has very low predictive power meaning the authors
were dependent upon adequately powered GWAS to
select their genetic instruments. Weak instrument bias
can be overcome by combining multiple associated
SNPs to increase the variance explained and ulti-
mately the strength of the instrument. However, as
more SNPs are included the risk of pleiotropic effects
increases, violating one of the main assumptions of
MR. This was potentially the case for total, HDL
and LDL cholesterol, where excluding one variant
also associated with AD meant the associations were
no longer significant [12]. There was considerable
variation in mean age between the included studies
(47–74 years), and the etiology and risk factor pro-
files of different dementia subtypes are known to vary
by age. Differences in the samples incorporated in
the included studies may therefore have contributed
to the heterogeneity observed. Potential survival and
diagnostic bias also remain key limitations of the
original included studies.
Conclusions
There is convincing evidence for a causal asso-
ciation of shorter telomeres with higher AD risk.
Uncertainties remain regarding other modifiable risk
factors as existing MR studies do not in themselves
provide convincing evidence for a causal link. Given
the methodological shortcomings identified and the
relatively limited number of MR studies it is impor-
tant to consider these findings cautiously and in
combination with other evidence from observational
studies and trials. That said observational studies do
not in themselves demonstrate causality and may
be consistently confounded. Furthermore, RCTs can
be expensive, impractical or unethical to conduct.
Larger well-designed MR studies are therefore likely
to be helpful in establishing the causal status of these
dementia risk factors.
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